The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015

Abstract

Aim A central task for the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is to produce an annual report of the latest data available on drug demand and drug supply in Europe. This paper is intended to facilitate a better understanding of, and easier access to, the main quantitative European level data sets available in 2015.Methods The European reporting system formally covers all 28 European Union (EU) Member States, Norway and Turkey and incorporates multiple indicators alongside an early warning system (EWS) on uncontrolled new psychoactive substances (NPS). While epidemiological information is based largely on registries, surveys and other routine data reported annually, the EWS collects case-based data on an ongoing basis. The 2015 reporting exercise is centred primarily on a set of standardized reporting tools. Results The most recent data provided by European countries are presented, including data on drug use, drug-related morbidity and mortality, treatment demand, drug markets and new psychoactive substances, with data tables provided and methodological information. A number of key results are highlighted for illustrative purposes. Drug prevalence estimates from national surveys since 2012 (last year prevalence of use among the 15-34 age band) range from 0.4% in Turkey to 22.1% in France for cannabis, from 0.2% in Greece and Romania to 4.2% in the United Kingdom for cocaine, from 0.1% in Italy and Turkey to 3% in the Czech Republic and the United Kingdom for ecstasy, and from 0.1% or less in Romania, Italy and Portugal to 2.5% in Estonia for amphetamine. Declining trends in new HIV detections among people who inject drugs are illustrated, in addition to presentation of a breakdown of NPS reported to the EU early warning system, which have risen exponentially from fewer than 20 a year between 2005 and 2008, to 101 reported in 2014. Conclusions Structured information is now available on patterns and trends in drug consumption in Europe, which permits triangulation of data from different sources and consideration of methodological limitations. Opioid drugs continue to place a burden on the drug treatment system, although both new heroin entrants and injecting show declines. More than 450 new psychoactive substances are now monitored by the European early warning system with 31 new synthetic cathinones and 30 new synthetic cannabinoid receptor agonists notified in 2014.

Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells

“…Due to its psychostimulatory effects, MDMA is a popular recreational drug [1]. Repeated dosing or a single high-dose of MDMA can produce a variety of neurological disorders including cognitive impairments and mood disturbances [2], and MDMA is toxic to the nervous system.…”

NPS and the emergent challenges for public health and psychiatry: an overview of the Portuguese situation

“…New data provided [15] Additionally, the use of NPS may be associated in some way to the numbers of emergency and inpatient episodes registered in last years. Supporting this assumption are the results from an European survey (leaded by Euro-DEN Plus) regarding hospital admissions in emergency departments due to psychoactive substances use.…”

European Monitoring Centre for Drugs and Drug Addiction has a vital role in the UK’s ability to respond to illicit drugs and organised crime

“…The UK will also need to find some way to continue to interact with the European Union Early Warning System on novel psychoactive substances 5. This area is changing rapidly,8 so up to date knowledge is vital for the UK’s drug strategy. The UK also risks exclusion from the EU Drugs Action Plan, an initiative that will strengthen surveillance in three domains: drug markets, drug related crime, and drug supply reduction 9.…”